Contraceptive Challenges in Women With Common Medical Conditions

Curtis, 2016, US medical eligibility criteria for contraceptive use, MMWR Recomm Rep, 65, 1, 10.15585/mmwr.rr6503a1

Curtis, 2016, US selected practice recommendations for contraceptive use, 2016, MMWR Recomm Rep, 65, 1, 10.15585/mmwr.rr6504a1

Gavin, 2017, Update: providing quality family planning services – recommendations from CDC and the US Office of Population Affairs, 2017, MMWR Morb Mortal Wkly Rep, 66, 1383, 10.15585/mmwr.mm6650a4

Zapata, 2019, Changes in US health care provider attitudes related to contraceptive safety before and after the release of national guidance, Contraception, 100, 413, 10.1016/j.contraception.2019.07.142

Ti, 2019, Postpartum hormonal contraception use and incidence of postpartum depression: a systematic review, Eur J Contracept Reprod Health Care, 24, 109, 10.1080/13625187.2019.1569610

Dragoman, 2018, A systemic review and meta-analysis of venous thrombosis risk among users of combined oral contraception, Int J Gynaecol Obstet, 141, 287, 10.1002/ijgo.12455

Ti, 2019, Safety and effectiveness of hormonal contraception for women who use opioids: a systematic review, Contraception, 100, 480, 10.1016/j.contraception.2019.08.006

2017, Practice Bulletin No. 186: Long-acting reversible contraception: implants and intrauterine devices, Obstet Gynecol, 130, e251

Oduyebo, 2019, Factors associated with postpartum use of long-acting reversible contraception, Am J Obstet Gynecol, 221, 43e1, 10.1016/j.ajog.2019.03.005

Daniels

Grigoryan, 2006, Contraception in perimenopausal women with diabetes mellitus, Gynecol Endocrinol, 22, 198, 10.1080/09513590600624317

Kemmeren, 2002, Risk of arterial thrombosis in relation to oral contraceptives (RATIO) study: oral contraceptives and risk of ischemic stroke, Stroke, 33, 1202, 10.1161/01.STR.0000015345.61324.3F

Khader, 2002, Oral contraceptives use and the risk of myocardial infarction: a meta-analysis, Contraception, 68, 11, 10.1016/S0010-7824(03)00073-8

Bergendal, 2014, Association of venous thromboembolism with hormonal contraception and thrombophilic genotypes, Obstet Gynecol, 124, 600, 10.1097/AOG.0000000000000411

Chi, 2011, Levonorgestrel-releasing intrauterine system for the management of heavy menstrual bleeding in women with inherited bleeding disorders: long-term follow-up, Contraception, 83, 242, 10.1016/j.contraception.2010.07.010

Martinelli, 2016, Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use, Blood, 127, 1417, 10.1182/blood-2015-08-665927

Ortizo, 2017, Exposure to oral contraceptives increases the risk for development of inflammatory bowel disease: a meta-analysis of case-controlled and cohort studies, Eur J Gastroenterol Hepatol, 29, 1064, 10.1097/MEG.0000000000000915

National Institutes of Health. Autoimmune Diseases of Rheumatoid Arthritis and Lupus. https://www.nih.gov/research-training/accelerating-medicines-partnership-amp/autoimmune-diseases-rheumatoid-arthritis-lupus. Accessed October 21, 2020.

2019, ACOG Practice Bulletin No. 206: use of hormonal contraception in women with coexisting medical conditions, Obstet Gynecol, 133, e128, 10.1097/AOG.0000000000003072

Tepper, 2020, Update to US medical eligibility criteria for contraceptive US, 2016: updated recommendations for the use of contraception among women at high risk for HIV infection, MMWR Morb Mortal Wkly Rep, 69, 405, 10.15585/mmwr.mm6914a3

Heikinheimo, 2011, The levonorgestrel-releasing intrauterine system in human immunodeficiency virus-infected women: a 5-year follow-up study, Am J Obstet Gynecol, 204, 126.e1, 10.1016/j.ajog.2010.09.002

Browne, 2008, Using an intrauterine device in immunocompromised women, Obstet Gynecol, 112, 667, 10.1097/AOG.0b013e318183464e

Edelman, 2014, Correcting oral contraceptive pharmacokinetic alterations due to obesity: a randomized controlled trial, Contraception, 90, 550, 10.1016/j.contraception.2014.06.033

Morelli, 2013, Efficacy of the levonorgestrel intrauterine system (LNG IUS) in the prevention of atypical endometrial hyperplasia and endometrial cancer: retrospective data from selected obese menopausal symptomatic women, Gynecol Endocrinol, 29, 156, 10.3109/09513590.2012.730579

2009, ACOG Practice Bulletin No. 105: Bariatric surgery and pregnancy, Obstet Gynecol, 113, 1405, 10.1097/AOG.0b013e3181ac0544

Lipton, 2007, AMPP advisory Group. Migraine prevalence, disease burden, and the need for preventive therapy, Neurology, 68, 343, 10.1212/01.wnl.0000252808.97649.21

2018, Headache Classification Committee of the International Headache Society (HIS) the International Classification of Headache Disorders, 3rd edition, Cephalalgia, 38, 1, 10.1177/0333102417738202

Tepper, 2016, Safety of hormonal contraceptives among women with migraine: a systemic review, Contraception, 94, 630, 10.1016/j.contraception.2016.04.016

Bounds, 2002, Observational series on women using the contraceptive Mirena concurrently with antiepileptic and other enzyme-inducing drugs, J Fam Plann Reprod Health Care, 28, 78, 10.1783/147118902101195992

Davis, 2014, Contraception for Women With Epilepsy, 135

Gaffield, 2011, The use of hormonal contraception among women taking anticonvulsant therapy, Contraception, 83, 16, 10.1016/j.contraception.2010.06.013

Smith, 2003, Cervical cancer and use of hormonal contraceptives: a systematic review, Lancet, 361, 1159, 10.1016/S0140-6736(03)12949-2

Cortessis, 2017, Intrauterine device use and cervical cancer risk: a systematic review and meta-analysis, Obstet Gynecol, 130, 1226, 10.1097/AOG.0000000000002307

Wentzensen, 2015, The Pill’s gestation: from birth control to cancer prevention, Lancet Oncol, 16, 1004, 10.1016/S1470-2045(15)00211-9

Wheeler, 2019, Intrauterine device use and ovarian cancer risk: a systematic review and meta-analysis, Obstet Gynecol, 134, 791, 10.1097/AOG.0000000000003463